However, administration of the GHRH analog tesamorelin to type 2 diabetes patients showed no changes in insulin response or diabetes control, despite decreasing cholesterol levels [134], suggesting that the effect is independent of the GHRH/GH/IGF-1 axis. This evidence concerns the gene GHRH and diabetes mellitus.